etidronate has been researched along with Gastroesophageal Reflux in 5 studies
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
Gastroesophageal Reflux: Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The findings supported the diagnosis of an acute exacerbation of a chronic risedronat-induced esophagitis caused by clindamycin." | 3.75 | [Acute exacerbation of a chronic esophagitis]. ( Göke, B; Ihrler, S; Kolligs, FT; Winkler-Budenhofer, UC, 2009) |
| "This study examined Barrett's esophagus (BE) risk factors in veterans to determine the association between risk of BE and use of oral bisphosphonates." | 1.39 | Oral bisphosphonates and the risk of Barrett's esophagus: case-control analysis of US veterans. ( Alsarraj, A; El-Serag, HB; Graham, DY; Kramer, JR; Lin, D; Parente, P; Ramsey, D; Rugge, M; Verstovsek, G, 2013) |
| " The oesophageal transit is rapid and given the rapid disintegration and gastric emptying, oesophageal contact occurring via reflux of risedronate was unlikely since most, if not all, of the dosage form exited from the stomach within 30 min." | 1.31 | Oesophageal transit, disintegration and gastric emptying of a film-coated risedronate placebo tablet in gastro-oesophageal reflux disease and normal control subjects. ( Blackshaw, PE; Dansereau, RJ; Frier, M; Hathaway, S; Juan, D; Li, Z; Long, P; Perkins, AC; Spiller, RC; Wilson, CG, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, D | 1 |
| Kramer, JR | 1 |
| Ramsey, D | 1 |
| Alsarraj, A | 1 |
| Verstovsek, G | 1 |
| Rugge, M | 1 |
| Parente, P | 1 |
| Graham, DY | 1 |
| El-Serag, HB | 1 |
| Binkley, N | 1 |
| Martens, MG | 1 |
| Silverman, SL | 1 |
| Derman, RJ | 1 |
| Greenwald, M | 1 |
| Kohles, JD | 1 |
| Bachmann, GA | 1 |
| Winkler-Budenhofer, UC | 1 |
| Ihrler, S | 1 |
| Göke, B | 1 |
| Kolligs, FT | 1 |
| Steele, P | 1 |
| Sparrowhawk, M | 1 |
| Perkins, AC | 1 |
| Wilson, CG | 1 |
| Frier, M | 1 |
| Blackshaw, PE | 1 |
| Juan, D | 1 |
| Dansereau, RJ | 1 |
| Hathaway, S | 1 |
| Li, Z | 1 |
| Long, P | 1 |
| Spiller, RC | 1 |
1 trial available for etidronate and Gastroesophageal Reflux
| Article | Year |
|---|---|
Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; | 2009 |
4 other studies available for etidronate and Gastroesophageal Reflux
| Article | Year |
|---|---|
Oral bisphosphonates and the risk of Barrett's esophagus: case-control analysis of US veterans.
Topics: Aged; Alendronate; Barrett Esophagus; Bone Density Conservation Agents; Case-Control Studies; Diphos | 2013 |
[Acute exacerbation of a chronic esophagitis].
Topics: Acute Disease; Anti-Bacterial Agents; Bone Density Conservation Agents; Clindamycin; Diagnosis, Diff | 2009 |
Patent news.
Topics: Animals; Antineoplastic Agents; Benzamides; Carbazoles; Drug Industry; Etidronic Acid; Gastroesophag | 2003 |
Oesophageal transit, disintegration and gastric emptying of a film-coated risedronate placebo tablet in gastro-oesophageal reflux disease and normal control subjects.
Topics: Aged; Aged, 80 and over; Esophagus; Etidronic Acid; Female; Gastric Emptying; Gastroesophageal Reflu | 2001 |